The Practice of Cystoscopy with Hydrodistention Since the 2011 American Urological Association Clinical Guideline on Interstitial Cystitis/Bladder Pain Syndrome.

Introduction: We determined the rate of cystoscopy with hydrodistention (CH) before and after the 2011 American Urological Association (AUA) amended clinical guideline, "Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome."

Methods: Clinical encounters with a diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS) where cystoscopy with and without hydrodistention was performed were identified in the Vizient® Clinical Data Base between January 2009 and February 2020. Demographic and clinical information such as patient age, gender, race, treating physician specialty, insurance type and type of hospital (teaching vs nonteaching) was recorded. Descriptive statistics, Wilcoxon 2-sample test and chi-square test were used to compare variables. An interrupted time series analysis was used to assess the change in CH rate following the June 2011 AUA guideline.

Results: From January 2009 to February 2020, 69,983 encounters were identified to have an IC/BPS diagnosis and to have undergone outpatient cystoscopy, of which 7,502 (10.7%) were CH. Compared to those not undergoing CH, subjects with IC/BPS undergoing CH were younger, predominantly female, Caucasian and had commercial insurance. Before the guideline, across all medical specialties, the base rate of CH was rising from 16.6% at a rate of 0.12% per month. Following guideline release, the CH rate dropped by 6.8%, declining 0.07% per month until February 2020. This pattern was most pronounced in urology relative to all other medical specialties.

Conclusions: The monthly average rate of CH among individuals with IC/BPS undergoing an outpatient CH dropped from nearly 17% before the 2011 AUA guideline to less than 10% in early 2020.